3 ASX Penny Stocks With Market Caps Over A$10M To Consider

In This Article:

As the ASX 200 gears up for a potential rise, buoyed by optimism of a year-end rally and positive movements in commodities like iron ore, Australian investors are keenly eyeing opportunities across various market segments. Despite its vintage connotations, the term "penny stock" remains relevant as it highlights smaller or less-established companies that can offer substantial value. By focusing on those with solid financial foundations and growth potential, investors can uncover hidden gems within this sector.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

Embark Early Education (ASX:EVO)

A$0.80

A$146.79M

★★★★☆☆

LaserBond (ASX:LBL)

A$0.55

A$64.47M

★★★★★★

Helloworld Travel (ASX:HLO)

A$2.05

A$333.78M

★★★★★★

Austin Engineering (ASX:ANG)

A$0.54

A$334.88M

★★★★★☆

MaxiPARTS (ASX:MXI)

A$1.83

A$101.23M

★★★★★★

SHAPE Australia (ASX:SHA)

A$2.79

A$231.32M

★★★★★★

Navigator Global Investments (ASX:NGI)

A$1.69

A$828.23M

★★★★★☆

Vita Life Sciences (ASX:VLS)

A$2.01

A$113.04M

★★★★★★

Big River Industries (ASX:BRI)

A$1.30

A$110.99M

★★★★★☆

Servcorp (ASX:SRV)

A$4.86

A$479.51M

★★★★☆☆

Click here to see the full list of 1,044 stocks from our ASX Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Avecho Biotechnology

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Avecho Biotechnology Limited is a biotechnology company focused on developing and commercializing human and animal health products using its proprietary drug delivery system and Tocopherol Phosphate Mixture in Australia, with a market cap of A$12.68 million.

Operations: The company generates its revenue from production activities amounting to A$0.34 million.

Market Cap: A$12.68M

Avecho Biotechnology, with a market cap of A$12.68 million, is pre-revenue with production activities generating A$0.34 million. Despite being unprofitable and experiencing increased losses over the past five years, Avecho benefits from having no debt and sufficient cash runway for more than a year based on current free cash flow. The company's experienced board and management team provide stability amidst its high share price volatility. Recent participation in the Bell Potter Healthcare Conference may enhance visibility within the sector as it continues to leverage its proprietary drug delivery system for future growth prospects.

ASX:AVE Debt to Equity History and Analysis as at Dec 2024
ASX:AVE Debt to Equity History and Analysis as at Dec 2024

Helloworld Travel

Simply Wall St Financial Health Rating: ★★★★★★